Disruption of lipid raft microdomains, regulation of cd38, tp53, and myc signaling, and induction of apoptosis by lomitapide in multiple myeloma cells
MEM Saeed, JC Boulos, SB Muecklich… - Cancer Genomics & …, 2022 - cgp.iiarjournals.org
Background/Aim: Multiple myeloma (MM) is characterized by accumulation of a malignant
clone of plasma cells in the bone marrow. Curative treatments are not yet available …
clone of plasma cells in the bone marrow. Curative treatments are not yet available …
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB–and caspase-8–dependent mechanisms
L Zhou, Y Zhang, MB Meads, Y Dai, Y Ning… - Blood …, 2021 - ashpublications.org
Interactions between the inhibitor of apoptosis protein antagonist LCL161 and the histone
deacetylase inhibitor panobinostat (LBH589) were examined in human multiple myeloma …
deacetylase inhibitor panobinostat (LBH589) were examined in human multiple myeloma …
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide
L Santo, T Hideshima, D Cirstea, M Bandi… - Clinical cancer …, 2011 - AACR
Purpose: Aurora kinases, whose expression is linked to genetic instability and cellular
proliferation, are being investigated as novel therapeutic targets in multiple myeloma (MM) …
proliferation, are being investigated as novel therapeutic targets in multiple myeloma (MM) …
Iguratimod-encapsulating PLGA-NPs induce human multiple myeloma cell death via reactive oxygen species and Caspase-dependent signalling
F Wang, M Younis, Y Luo, L Zhang, L Yuan - International …, 2021 - Elsevier
Human multiple myeloma (MM) is a currently incurable haematopoietic malignancies. Our
research investigate the anti-tumour effect of iguratimod (IGU) encapsulated in poly (lactic …
research investigate the anti-tumour effect of iguratimod (IGU) encapsulated in poly (lactic …
Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?
AA Khan, CN Harrison… - British journal of …, 2015 - Wiley Online Library
Summary Deregulated Hedgehog (Hh) signalling activity may be associated with a broad
range of cancer types and hence has become an attractive target for therapeutic …
range of cancer types and hence has become an attractive target for therapeutic …
Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway
M Li, C Chen, Q Wang, X Jiang, L Tan, Y Huang… - Cancer Cell …, 2021 - Springer
Background Multiple myeloma (MM) is the most common malignant hematological disease
in the people worldwide. Glaucocalyxin A (GLA) is a bioactive ent-kauranoid diterpenoid …
in the people worldwide. Glaucocalyxin A (GLA) is a bioactive ent-kauranoid diterpenoid …
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
C Gu, Y Wang, L Zhang, L Qiao, S Sun, M Shao… - Journal of Experimental …, 2022 - Springer
Background Currently, multiple myeloma (MM) is still an incurable plasma cell malignancy in
urgent need of novel therapeutic targets and drugs. Methods Bufalin was known as a highly …
urgent need of novel therapeutic targets and drugs. Methods Bufalin was known as a highly …
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades, CS Mitsiades, V Poulaki… - Blood, The Journal …, 2002 - ashpublications.org
Thalidomide (Thal) achieves responses even in the setting of refractory multiple myeloma
(MM). Although increased angiogenesis in MM bone marrow and the antiangiogenic effect …
(MM). Although increased angiogenesis in MM bone marrow and the antiangiogenic effect …
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with …
SG Eckhardt, SD Baker, CD Britten… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: To evaluate the toxicity and pharmacologic behavior of the novel mushroom-
derived cytotoxin irofulven administered as a 5-minute intravenous (IV) infusion daily for 5 …
derived cytotoxin irofulven administered as a 5-minute intravenous (IV) infusion daily for 5 …
[HTML][HTML] The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
S Hernández-García, L San-Segundo… - …, 2017 - ncbi.nlm.nih.gov
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several
malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in …
malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in …